PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.10462021365977-987The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 DiabetesInha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Leehttp://e-enm.org/upload/pdf/enm-2021-1046.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.1046, http://e-enm.org/upload/pdf/enm-2021-1046.pdf
Journal of Diabetes and its Complications10.1016/j.jdiacomp.2008.07.0032009236427-433Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agentsMatteo Anselminohttps://api.elsevier.com/content/article/PII:S105687270800072X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S105687270800072X?httpAccept=text/plain
Diabetes & Metabolism10.1016/j.diabet.2018.10.0032019452110-121Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetesA.J. Scheenhttps://api.elsevier.com/content/article/PII:S1262363618301976?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1262363618301976?httpAccept=text/plain
Chronic Coronary Artery Disease10.1016/b978-0-323-42880-4.00030-32018479-487Secondary Prevention of Coronary Artery DiseaseKarol E. Watson, Yuanlin Guo, Sheila Sahnihttps://api.elsevier.com/content/article/PII:B9780323428804000303?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:B9780323428804000303?httpAccept=text/xml
Diabetes & Metabolism10.1016/j.diabet.2014.03.0042014403176-185Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisalA.J. Scheen, B. Charbonnelhttps://api.elsevier.com/content/article/PII:S1262363614000652?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1262363614000652?httpAccept=text/plain
Yearbook of Cardiology10.1016/s0145-4145(09)79551-620092009312-313Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After coronary Artery Bypass SurgeryB.J. Gershhttps://api.elsevier.com/content/article/PII:S0145414509795516?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0145414509795516?httpAccept=text/plain
Yearbook of Medicine10.1016/s0084-3873(09)79450-720092009402-404Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass SurgeryB.J. Gershhttps://api.elsevier.com/content/article/PII:S0084387309794507?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0084387309794507?httpAccept=text/plain
Atherosclerosis Supplements10.1016/s1567-5688(07)71456-3200781126-127PO16-446 SUSTAINED SUBOPTIMAL SECONDARY PREVENTION OF CORONARY ARTERY DISEASE IN TYPE 2 DIABETES: AN ANALYSIS OF 41300 PATIENTS OVER 3 YEARSH. Voller, K. Bestehorn, C. Jannowitz, R. Reibis, K. Wegscheiderhttps://api.elsevier.com/content/article/PII:S1567568807714563?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1567568807714563?httpAccept=text/plain
Diabetes and Vascular Disease Research10.1177/14791641198456122019165399-414Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndromeAngelo Avogaro, Enzo Bonora, Agostino Consoli, Stefano Del Prato, Stefano Genovese, Francesco Giorginohttp://journals.sagepub.com/doi/pdf/10.1177/1479164119845612, http://journals.sagepub.com/doi/full-xml/10.1177/1479164119845612, http://journals.sagepub.com/doi/pdf/10.1177/1479164119845612
Chronic Coronary Artery Disease10.1016/b978-0-323-42880-4.00024-82018355-373Managing Chronic Coronary Artery Disease in Patients with DiabetesNikolaus Marx, Sebastian Reithhttps://api.elsevier.com/content/article/PII:B9780323428804000248?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:B9780323428804000248?httpAccept=text/xml